Overview

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Status:
Active, not recruiting

Trial end date:
2027-09-01

Target enrollment:

Participant gender:

Summary

The investigator(s) hypothesize that Rituximab together with combination chemotherapy, followed by Rituximab maintenance therapy, will provide better disease control with improved response rates and overall survival in patients with previously untreated Mantle Cell Lymphoma (MCL).

Phase:

Phase 2

Details

Lead Sponsor:

University of Miami

Treatments:

Cyclophosphamide
Cytarabine
Doxorubicin
Etoposide
Etoposide phosphate
Ifosfamide
Isophosphamide mustard
Leucovorin
Liposomal doxorubicin
Mesna
Methotrexate
Rituximab
Vincristine